We interpret our findings to indicate that catalpol can positively facilitate OL regeneration by promoting the activation of the GEF-Cdc42/Rac1 signaling pathway, suggesting that this drug is a promising candidate for the clinical treatment of demyelinating diseases. This evidence concerns the gene CDC42 and demyelinating disease.